Basepoint Wealth’s Gilead Sciences GILD Stock Holding History

Basepoint Wealth’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60.4K	Buy	434 +3	+0.7%	+$420	0.03%	196
2025 Q4	$52.9K	Buy	+431	New	+$52.4K	0.03%	207
2024 Q2	–	Sell	-3,319	Closed	-$243K	–	113
2024 Q1	$243K	Sell	3,319 -3,472	-51%	-$267K	0.18%	102
2023 Q4	$550K	Sell	6,791 -3,812	-36%	-$297K	0.44%	56
2023 Q3	$795K	Sell	10,603 -26	-0.2%	-$2K	0.65%	38
2023 Q2	$819K	Buy	10,629 +44	+0.4%	+$3.51K	0.68%	39
2023 Q1	$878K	Buy	10,585 +217	+2%	+$18K	0.73%	36
2022 Q4	$890K	Sell	10,368 -224	-2%	-$17.7K	0.79%	32
2022 Q3	$653K	Buy	10,592 +2,975	+39%	+$188K	0.7%	40
2022 Q2	$471K	Buy	+7,617	New	+$472K	0.49%	50

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Basepoint Wealth's GILD Position: Q1 2026 in Review

Basepoint Wealth increased its Gilead Sciences (GILD) stake by 0.7% in Q1 2026, buying an estimated $420 and bringing the position to 434 shares worth $60.4K. The position accounts for 0.03% of the portfolio, ranked #196.

Basepoint Wealth first reported a position in GILD in Q2 2022 and has held it in 10 quarters since. The position peaked at $890K in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Basepoint Wealth held 434 shares of Gilead Sciences worth $60.4K as of Q1 2026.
Basepoint Wealth bought 3 Gilead Sciences shares in Q1 2026, an estimated $420.
Gilead Sciences made up 0.03% of Basepoint Wealth's portfolio in Q1 2026, its #196 holding.
Basepoint Wealth first reported a position in Gilead Sciences in Q2 2022 and has held it in 10 quarters since.
Basepoint Wealth's Gilead Sciences position peaked at $890K in Q4 2022.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Basepoint Wealth's 13F filing for Q1 2026, filed 7 May 2026.